Human medicines European public assessment report (EPAR): Dazluma, troriluzole, Status: Application withdrawn
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025
Summary of opinion: Zoonotic Influenza Vaccine Seqirus, 25/04/2025 Positive
Summary of opinion: Adcetris, 25/04/2025 Positive
New treatment against Duchenne muscular dystrophy
First treatment against severe thyroid eye disease
Summary of opinion: Adempas, 25/05/2025 Positive
Withdrawn application: Ngenla, 20/12/2024
Opinion/decision on a Paediatric investigation plan (PIP): Rydapt, Midostaurin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps);Oncology, PIP number: P/0068/2024
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024